University of British Columbia
Pharmacokinetic modeling of time-dependent clearance of therapeutic antibodies : clinical implications and physiological mechanisms
Abstract
dc:descriptionTherapeutic antibodies frequently demonstrate time-dependent pharmacokinetics (TDPK) where drug clearance declines throughout treatment, particularly in oncology and inflammatory disease. The decline is often more pronounced in patients who respond well to therapy. This imposes a confounding effect on exposure-response analysis because it is unclear whether the drug exposure influences the probability of a therapeutic response, or the response influences the drug exposure over time. As a result, the optimal dose of the drug may be difficult to identify despite extensive clinical study. In this dissertation, mathematical modeling of antibody pharmacokinetics was applied to understand and provide insights on the impact of TDPK on clinical study design and the mechanisms that cause it to occur. Through clinical trial simulation of antibodies with time-dependent clearance, study designs with patients randomized to receive different dose levels with at least a three-fold dose range were shown to be less susceptible to confounded results. Additionally, mechanistic modeling was applied to quantify two distinct causes of TDPK in oncology. Accelerated antibody clearance can be caused by systemic inflammation in advanced cancer: when drug treatment is successful, the inflammatory state improves and clearance declines. A physiologically based pharmacokinetic (PBPK) model was constructed to describe the change in clearance as function of albumin levels, a serum biomarker of cancer inflammation. The model was shown to be predictive of changes in clearance seen in immune checkpoint inhibitors., A second mechanistically distinct PBPK model was assembled to describe the changing clearance of therapeutic antibodies that treat multiple myeloma, a cancer of antibody-secreting cells. This cancer type is associated with high levels of a serum protein called M-protein that interferes with the interaction between therapeutic antibodies and neonatal Fc receptor (FcRn) which is responsible for prolonging the half-life of antibodies. The model accurately quantified the changing clearance over time seen with isatuximab, a therapeutic antibody for treatment of multiple myeloma. Mathematical modeling of antibody TDPK provides a valuable tool to describe, predict, and understand the complex longitudinal patterns that confuse dose optimization. Untangling the complexity of time-dependent clearance is essential to accurately select optimal doses and deliver benefit to patients in need.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy - PhD
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Pharmaceutical Sciences
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Proctor, Jeffrey Ryan
- Contributors dc:contributor
-
- Wong, Harvey
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/95174